PDS Biotech Announces PDS0202 Elicits Active Neutralization Of Multiple Influenza Strains In Preclinical Studies
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology Corporation (NASDAQ:PDSB) announced that its investigational universal influenza vaccine PDS0202 demonstrated active neutralization across multiple influenza viruses in preclinical studies. The vaccine also provided protection against infection after challenged with high doses of the H1N1 virus in ferrets. The data were presented at the 9th European Scientific Working Group on Influenza (ESWI) Conference. PDS0202 combines PDS Biotech's Infectimune® novel investigational immune activating platform with proprietary Computationally Optimized Broadly Reactive Antigens (COBRA) influenza antigens.
September 20, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PDS Biotech's PDS0202 vaccine has shown promising results in preclinical studies, which could potentially lead to a universal influenza vaccine. This could significantly boost the company's profile and market position.
The successful preclinical results of PDS0202, a universal influenza vaccine, could potentially lead to a breakthrough in the influenza vaccine market. This could significantly boost PDS Biotech's market position and stock value in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100